AB0532 MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL

Christopher Em Griffiths; Kim Papp; Michael Song; Megan Miller; Yin You; Yaung‐Kaung Shen; Andrew Blauvelt

doi:10.1136/annrheumdis-2021-eular.960

Related publications

Article2019

Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial

Christopher Em Griffiths, Kim Papp, Mengsa Song, Megan Miller, Yin You, Y-K Shen, Chenglong Han, Andrew Blauvelt

Article2019

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

Kristian Reich, Christopher Em Griffiths, Kenneth B. Gordon, Kim Papp, Michael Song, B. Randazzo, Shu Li, Yaung‐Kaung Shen, Chenglong Han, Alexa B. Kimball, April W. Armstrong, Peter Foley, Andrew Blauvelt

Article2018

Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis

Christopher Em Griffiths, KA Papp, Michael Song, B. Randazzo, S Li, Y-K Shen, Chenglong Han, Andrew Blauvelt

Article2018

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Christopher Em Griffiths, Kim Papp, Alexa B. Kimball, B. Randazzo, Michael Song, Shu Li, Yaung‐Kaung Shen, Andrew Blauvelt

Article2020

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Christopher Em Griffiths, Kim Papp, Michael Song, Megan Miller, Yin You, Yaung‐Kaung Shen, Chenglong Han, Andrew Blauvelt

AB0532 MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL

Discussion(0)